AI in Drug Development: Luminari CRO joined NVIDIA Inception to speed AI-powered clinical trial protocol development while keeping regulatory rigor. Investor Outlook: Omada Health set long-term goals of 20%+ annual revenue growth, 80% non-GAAP gross margin, and 30% adjusted EBITDA margin at its inaugural Investor Day. Clinical Trials Pipeline Risk: The UK’s Royal College of Physicians warns clinical academic careers are shrinking, threatening government ambitions to expand trial access. Occupational Health Leadership: Dr. John Howard was reappointed to lead NIOSH and the World Trade Center Health Program, which monitors care for 140,000+ responders and survivors. Rare Disease Watch: FDA has started a priority review of Roche’s Enspryng for MOGAD, with a decision due in January. Healthcare AI & Security: A new survey finds payers and providers are still struggling with AI readiness, including shadow AI and cybersecurity threats. GLP-1 Scrutiny: A US analysis highlights how much major drugmakers paid prescribers, raising questions patients can now ask about those relationships. EMS Oversight: Seattle officials are pressing for accountability after concerns about an out-of-state nurse line and AI-assisted 911 triage. NHS Demand Signals: UK A&E saw record summer volumes, but the share seen within four hours hit a high. Medical Tourism & Tech: Korea’s medical tourism push is leaning on AI plus anti-aging care to attract international patients.